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Abstract：The goal of our study is to develop a molecular imaging in gastrointestinal tract using 
infrared fluorescence endoscope (IRFE) and labeled antibodies with indocyanine green (ICG)-
derivative in detecting cancerous tissue. IRFE consisted of an infrared endoscope equipped with 
excitation (710-790 nm) and barrier (810-920 nm) filters. We have developed ICG-N-hydroxy sulfo 
succinimide ester (ICG-sulfo-OSu) and 3-ICG-acyl-1,3-thiazolidine-2-thione (ICG-ATT) as an 
infrared fluorescent-labeling reagent. ICG-derivative-labeled anti-human carcinoembryonic antigen 
(CEA) antibody and MUC1 antibody were prepared. Freshly resected specimens with gastric cancer 
were observed by IRFE after reaction with ICG-derivative labeled antibodies. It resulted in positive 
fluorescence at the tumor location by IRFE, and the immnofluorescent images correlated well with 
the tumor sites. The immunohistochemical studies suggested the intensity of IR fluorescence of ICG-
ATT-MUC1 stronger than ICG-sulfo-OSu. We conclude that an anti-CEA or MUC1 antibody with 
affinity for cancerous lesions and labeled with ICG-derivative can be imaged with this IRFE. Specific 
antibodies labeled with ICG-derivative with the reinforcing agent and electronic device can visualize 
cancer proteins generating a strong enough fluorescent signal.
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1. Introduction
Diagnostic endoscopy has been used for early detection 
of gastrointestinal neoplasias1). Diagnostic accuracy can 
be enhanced by good training and adequate experience, 
but diagnosis using conventional endoscopy is essentially 
limited because it is based on morphological changes 
and/or discoloration2, 3). This limitation is overcome by 
histopathological diagnosis of a biopsy specimen, but biopsy 
takes extra time and expense and is not advisable for patients 
taking anti-coagulants or anti-platelet medicine. Thus, the 
future of endoscopic diagnosis is likely to be a combination 
of biomarkers and instrumental technology. ‘Molecular 
imaging’ is a concept representing the most novel imaging 
methods in the field of endoscopy, which have been called 
‘immunoscopy’4), ‘bioendoscopy’5), and ‘optical biopsy’6). 
We have attempted to develop a novel imaging method using 
antibodies labeled with a fluorescent marker and imaging 
modalities7).
2. Characteristics of infrared fluorescence
Infrared radiation is light with wavelengths between 780 
nm and 100 μm, and it has high permeability and safety 
compared to ultraviolet rays. These characteristics have 
been applied to various technologies such as non-destructive 
analysis of agricultural products, and infrared photography 
has been especially investigated in the medical field 8, 9). 
Infrared endoscopy has been used as a special diagnostic 
tool for examination of the gastrointestinal tract with or 
without intravenous injection of indocyanine green (ICG)10-13); 
ICG is widely used as a reagent for clinical examination of 
hepatic function14). ICG is a fluorescent agent that absorbs 
infrared rays and produces visible spots at the maximum 
上村修三郎「がん研究」奨励賞受賞講演
334 四国歯誌　第21巻第２号　2009 Molecular Imaging in Endoscopic Oncology（MUGURUMA） 335
wavelength of 805 nm15). ICG emits wavelengths of 807-832 
nm on excitation at around 770 nm16-18). Taking advantage of 
this characteristic, infrared fluorescence is used for retinal 
angiography19) and the evaluation of burn depth20) and the 
patency of cardiac venografts21). Recently, this property 
was applied to gastrointestinal blood vessels using a CCD 
camera22). In the living body, components or elements emit 
fluorescence of 310-540 nm when excited at 280-370 nm. 
In addition, there is little background noise in the living 
body23), especially in the digestive tract, which makes infrared 
fluorescence a likely candidate for development as a novel 
diagnostic system24, 25). Several kinds of labeling agents 
for detecting carcinomas in the digestive tract have been 
reported26-28), some of which fluoresce in visible or ultraviolet 
rays. However, application of ultravidet is not suitable 
because it damages living tissue29). ICG seems to be a suitable 
molecule for immunofluorescent diagnosis in the digestive 
tract such as esophagus, stomach, and colon because of its 
spectral properties and low toxicity. 
3. Fluorescent agents
Although ICG binds albumin in a non-covalent way in the 
blood, it lacks a protein-binding group to bind antibodies. 
Therefore, we developed an ICG-N-hydroxysulfosuccinimide 
ester (ICG-sulfo-OSu) (Fig. 1) that has the ability to bind to 
proteins30). The physiochemical characteristics resembled 
those of ICG: the absorption maximum was 795 nm, and it 
has a specific fluorescence emission at 807 nm upon excitation 
at 768 nm. However, the fluorescence intensity was not 
sufficient when it was labeled with an antibody. Consequently, 
Nagao et al. developed ICG-acylthiazolidinethione (ICG-ATT) 
(Fig. 2)31), which consists of the ICG skeleton, an alkyl side 
chain, and the thiazolidinethione amide group. The absorption 
maximum was 789 nm, and the fluorescent maximum was 
830 nm upon excitation at 765 nm, reflecting the structure 
of the original ICG-dye moiety. Both materials proved to 
be near-infrared fluorescent agents, but it is unknown if 
ICG derivatives are toxic to living body in a clinical setting. 
Although precise toxicity tests have not been performed yet, 
ICG derivatives are expected to be non-toxic because the 
basic structures of these materials are similar to ICG, which is 
non-toxic. 
4. Labeled antibodies
First, we labeled an anti-epithelial membrane antigen 
(EMA) antibody with ICG-sulfo-OSu. Although the anti-
EMA antibody is not cancer-specific, this antibody is cross-
reactive with normal epithelium in the digestive tract and has 
a relatively high sensitivity32). Therefore, we first confirmed 
the sensitivity and specificity of immunofluorescence of the 
labeled antibody. Anti-EMA antibody (Dako, Denmark) was 
labeled with ICG-sulfo-OSu by our standardized method. 
Anti-EMA antibody (2.8 mg) was dissolved in 4 ml of 100 
mM sodium bicarbonate buffer (pH 8.5), and 40 μl of 6 mM 
ICG-sulfo-OSu dissolved in dimethylsulfoxide was added, 
followed by incubation at 37℃ for 1 hour. Based on our 
previous study, the molecular ratio of anti-EMA antibody to 
ICG-sulfo-OSu was 1:12. The reaction mixture was purified 
with a Sephadex G-25M column (PD-10, Pharmacia, Sweden) 
using 50 mM phosphate-buffered saline (PBS) as an eluent. 
The dye-conjugated antibody was separated from the free dye. 
The greenish solution of ICG-sulfo-OSu labeled anti-EMA 
antibody was immediately freeze-dried. The physiochemical 
characters of the labeled antibody were similar to those of 
ICG. After confirmation of adequate immunofluorescence 
from this labeled antibody, we attempted to develop a cancer-
specific labeled antibody. In fact, various cancer-specific 
antibodies, such as the anti-carcinoembiyonic antigen (CEA) 
antibody, have been used as labeled antibodies for the 
diagnosis of gastrointestinal cancer33). We have also labeled an 
anti-CEA antibody (Chemicon International Inc., CA, USA), 
which has a high sensitivity for gastrointestinal cancer34), with 
ICG-sulfo-OSu. The excitation and emission spectra of ICG-
sulfo-OSu labeled anti-CEA antibody was also similar to that 
of ICG18). Although the labeled anti-CEA antibody showed 
efficient immunofluorescence, we developed a new labeled 
antibody using a more sensitive tumor marker. Mucin, a 
glycoprotein containing a large amount of sugar, is the main 
Fig. 1 The chemical structure of ICG-sulfo-OSu. ICG-sulfo-
OSu has an ester group, a characteristic chemical 
structure capable of binding to various antibodies 
(squared).
Fig. 2 The chemical structure of ICG-ATT. ICG-ATT is also 
an infrared fluorescent-labeling reagent useful for 
proteins and amino acid compounds.
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component of mucus, and the peptide structure of the mucin 
core protein has been clarified35). The specific expression 
of mucin in various cancers has been reported, and we also 
studied the stainingpattern and evaluated its sensitivity 
in gastrointestinal cancers 36). Based on its relatively high 
sensitivity37, 38), we labeled an anti-MUC1 antibody (MY.1E12; 
kindly provided by Prof. Tatsuro Irimura, The University of 
Tokyo) with ICG-ATT.
5. Imaging modality
Based on the characteristics of ICG-derivatives, a prototype 
of infrared fluorescence endoscopy was developed to observe 
the human gastrointestinal tract (Fig. 3)29). The system 
consisted of an infrared endoscope (Olympus XGIF-Q40IR, 
Olympus) coupled with an image-capturing device. The light 
source, a 300 W xenon lamp, was also equipped with an 
excitation filter and a barrier filter, making it was possible to 
observe fluorescence with the infrared excitation light and 
produce normal images under visible light. The Intensified 
CCD (ICCD) camera was optically connected with the scope 
through an adapter into which the barrier filter was inserted. 
The new endoscopy system with a CCD at its tip has a 
greatly improved resolution: this system comprises of a light 
source apparatus, an infrared fluorescence endoscope, and 
image analysis software, which is the same as that used for 
a conventional system40). The light source apparatus (XCLV-
260HP-IRF, Olympus) has three built-in filters; an infrared ray 
cut filter, an infrared ray pass filter, and a RGB filter. White 
light produced by a xenon arc lamp goes through the infrared 
ray cut filter or infrared ray pass filter and then through the 
RGB rotation filter. The infrared ray cut filter is used for 
conventional observation and the infrared ray pass filter for 
infrared fluorescence observation. The infrared ray pass filter 
can transmit rays of wavelengths between 540 nm and 560 
nm in addition to infrared rays of wavelengths between 680 
nm and 770 nm. The reflected light of the former rays allow 
us to know where in the stomach we are looking during 
infrared fluorescence observation. The RGB rotation filter 
can transmit light in the near-infrared region as well as the 
visible region. The infrared fluorescence endoscope (XGIFQ-
240IRFZ, Olympus) is equipped with both a CCD with high 
resolution for conventional observation and a CCD with high 
sensitivity for infrared fluorescence observation at the top. 
These two CCDs can be switched from one to another with 
a single touch of the button of the endoscope in conjunction 
with the switch from one filter to another (the infrared ray cut 
filter and infrared ray pass filter) in the light source apparatus. 
Infrared rays excite the ICG-derivative-labeled antibody to 
emit fluorescence, which is subjected to barrier filters (825 to 
945 nm) placed in front of the CCD for infrared fluorescence 
and is monitored as green signals on a pseudo-color display 
with an image processor (XCV-260HP-IRF, Olympus).
6. Ex vivo study of immunofluorescence 
with human stomach
The resected stomach tissue was treated with warm water of 
37℃ containing 20000 U of Pronase, 1 g of NaHCO3, and 4 
mg of dimethylpolysiloxane for 15 min at room temperature 
to remove mucus adhering to the mucosa. The sample was 
treated with normal horse serum (blocking serum) for 15 min. 
The surface of the lesion and normal mucosa were then treated 
with ICG-derivative-labeled antibody for 60 min at room 
temperature39). Then, normal mucosa and the cancerous area 
were compared using the infrared fluorescence endoscope. 
The immunofluorescence of CEA labeled with ICG-sulfo-
Osu was strongly recognized, while there was no obvious 
fluorescence in the normal mucosa (Fig. 4a, b). Paraffin 
sections of the specimen were stained with CEA antibody, and 
the fluorescence-positive sites and the immunoreaction with 
non-labeled CEA antibody corresponded well.
7. Reinforcement of fluorescence intensity
Some types of drugs (octylglucoside, OG) are known to be 
useful as reinforcement agents41). The peak fluorescence 
Fig. 3 The schema of infrared fluorescence endoscope 
system. This system consisted of an infrared endoscope 
(Olympus XGIF-Q40IR, OLYMPUS) coupled with 
an image-capturing device. The light source that 
includes a 300 W xenon lamp which was equipped 
with an excitation filter and a barrier filter, so that it 
was possible to observe fluorescence with infrared 
excitation light and normal images under visible light. 
The ICCD camera was optically connected with the 
scope through an adapter into which the barrier filter 
was inserted (Ito S, et al. Endoscopy 33: 849-853, 
2001).
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wavelength lengthened with increasing concentration; an 
increase in the OG concentration from 10 to 100 mM resulted 
in a shift of the peak fluorescence wavelength from 800 to 817 
nm. In a study with paraffin sections of human gastric cancer, 
slight fluorescence was observed without OG; however, 
with 100 mM OG, marked fluorescence was observed42). 
In another study, we assessed the relationship between the 
fluorescence and protein ratio (F/P ratio) and fluorescence 
intensity43). During purification of the labeled antibody, the 
concentration of each labeling compound reacting with 1 
molecule of the antibody was varied as follows: 4, 8, 16, 
and 32 molar equivalents. Subsequently, the intensity of 
fluorescence was evaluated by spectroscopy and infrared 
fluorescence microscopy. When the fluorescent antibody 
labeled with ICG-ATT was used at an F/P ratio of 2.94 or 
4.18, clear and specific fluorescent images of the antigen were 
obtained. When the ICG-ATT-labeled antibody was used at an 
F/P ratio of 6.50 or 6.75, the fluorescence intensity decreased 
and the fluorescent images of the antigen became unclear. 
Therefore, the lower binding molar ratios of ICG-ATT were 
more useful for labeling the antibody. In previous studies, the 
whole IgG molecule was commonly used for preparation of 
labeled antibodies. However, labeled IgG displays insufficient 
sensitivity and specificity, probably resulting from nonspecific 
binding of the Fc fragment to target cells or molecular 
structure-dependent interference between fluorochromes. We 
characterized an Fc-free fluorescence-labeled Fab fragment, 
which was expected to yield more-specific binding to target 
cells than the whole IgG molecule. An anti-mucin antibody 
and ICG-ATT were used as the labeled antibody and labeling 
compound, respectively. Paraffin sections of excised gastric 
cancer tissues were subjected to staining. The labeled whole 
IgG molecule (ICG-ATT-labeled IgG) and the labeled Fab 
fragment (ICG-ATT-labeled Fab) were prepared according to 
a previous report, and the features of fluorescence microscopy 
images obtained from paraffin sections were compared. 
The fluorescence intensity obtained from paraffin sections 
of excised gastric cancer tissues tended to be greater with 
ICG-ATT-labeled Fab than with ICG-ATT-labeled IgG. 
Fragmentation of antibodies is considered to contribute to 
improved sensitivity and specificity of labeled antibodies for 
detection of micro gastrointestinal cancers44). 
8. In vivo reaction for exogenous antibody
In vivo immunostaining is essential for utilization of this 
technique in endoscopic diagnosis; however, no method has 
been established yet45). We examined in vivo immunostaining 
using nude mice. A human gastric cancer was transplanted into 
the mice, and the tumor was exposed under ether anesthesia. A 
tissue sample was collected after treatment with an antibody, 
and immunostaining was performed using the avidin-biotin 
complex method. Where anti-MUC1 mucin antibody had 
been applied in vivo to the cleaved surface of the grafted 
gastric cancer, the reaction product was demonstrated by the 
luminosity of the neoplastic tissue. In positive controls, strong 
reactivity was seen, but in the negative control, reactivity was 
not observed46).
9. Future perspectives in diagnostic endoscopy
Diagnostic accuracy in endoscopic imaging can be enhanced 
by better training, including education and experience in 
lesion recognition and morphological diagnosis. An important 
characteristic of electroendoscopy is the ability to isolate 
lesions to facilitate their detection and qualitative diagnosis. 
There are numerous methods for image enhancement and 
adjunctive techniques that rely on the differential tissue effects 
of lights2, 47-53). Techniques exploiting previously unused 
properties of light have demonstrated the potential to enhance 
the ability to make clinical diagnoses without removing tissue 
as has been standard practice of decades. “Optical biopsy” 
is term that describes an image enhancement system that can 
detect dysplasia and neoplasia in real time. Although this 
technique is not yet widely available, enthusiasm for such 
techniques has grown, as has research in their potential clinical 
utility54). In the future, diagnosis will be based on the fact that 
diseases are defined by their molecular characteristics, rather 
than their morphology. “Endoscopic molecular imaging” to 
visualize the enzymatic and protein properties of tissues will 
be possible. When this procedure is realized, biomarkers will 
take a more important role in imaging.
However, at present, manufacturing limits future technologic 
Fig.4 Infrared fluorescence imaging of freshly resected 
human gastric cancer tissue using ICG-sulfo-OSu-
labeled anti-human carcinoembryonic antigen (CEA) 
antibody and an infrared fluorescence endoscope. The 
cancerous areas were stained with the fluorescent anti-
CEA antibody complex. a. The image observed under 
visible rays. b. The image observed under infrared rays 
(Ito S, et al. Endoscopy 33: 849-853, 2001).
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innovation in gastroenterology. Pharmaceutical companies 
are hesitant to invest in the development of novel diagnostic 
drugs, owing to the inability to precise predict marketing in 
this field and anticipate reimbursement, leading to loss of 
opportunities for the acquisition of advanced technology3, 24). It 
is important that instrumentation and drugs be developed and 
promoted efficiently through the cooperation of the industry, 
national grants, and the efforts of the academic sectors55).
This work was supported in part by Uemura Shusaburo 
Foundation. 
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